38LOW

ATH

ALTERITY FPO [ATH]
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0080 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical71
Catalyst53
Sentiment50
Fundamental77
Momentum56
Risk Gate35
Get alerts when ATH's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track ATH — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Knocking on the door of resistance — if it punches through, things could get interesting
  • On a tear — up 14.3% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.12, so it's outpacing the pack
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Strong cash runway (14 quarters)
  • Moderate P/S ratio (13.1x)
  • Strong revenue growth (+75%)
  • Near 52-week low (17% of range)
  • Small-cap ($20-100M)
  • Capital raise activity (1 events)
  • CANSLIM I: Institutional ownership (19%)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +75% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.72%/day)
  • Penny stock risk ($0.008)
  • RBA hiking (-3pts)
  • Dilution risk: technical breakout with recent capital raise

Risk Signals

  • Stochastic is stretched into overbought — could need a breather
  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-220%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 27% over the past year
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about ATH
"What's driving ATH's score?" "How does ATH compare to peers?" "Key risks for ATH?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Proposed issue of securities - ATH
NONE Unmarketable Parcel Sale Facility
NONE Alterity to Participate in the Bell Potter Healthcare Summit
Announcement tone +3pts

Recent ASX Announcements

2026-03-19 Proposed issue of securities - ATH
2026-03-12 Unmarketable Parcel Sale Facility
2026-03-09 Alterity to Participate in the Bell Potter Healthcare Summit
2026-03-03 Dr Daniel Claassen as Chief Medical Advisor
2026-02-25 Half Yearly Report and Accounts PRICE SENSITIVE

Key Metrics

$87.0M
Market Cap
3.6M
Avg Volume
0.4x
Vol Ratio
$0.01 — $0.02
52-Week Range
0.1%
Short Interest
N/A
Cash Runway
-47.0%
ROE
-219.9%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 76%
LLeader vs LaggardlaggardRS: 0
IInstitutional SponsorshippassInst: 19%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #94 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:ATH vs ATXATH vs PNVATH vs IMM
Scout Pro — Deeper Analysis for ATH
Try Pro free for 30 days
Share this analysis

Track ATH and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required